JPMorgan analyst Anupam Rama raised the firm’s price target on Neurocrine Biosciences to $139 from $134 and keeps an Overweight rating on the shares. The analyst updated the company’s model to reflect new Ingrezza revenue assumptions, expenses, and share count.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX:
- Neurocrine announces settlement of INGREZZA ANDA litigation
- Neurocrine price target lowered to $121 from $128 at RBC Capital
- Neurocrine price target lowered to $100 from $111 at BMO Capital
- Neurocrine price target lowered to $114 from $116 at Mizuho
- Neurocrine price target lowered to $137 from $145 at BofA